OUR LEAD MOLECULE PN6047 has the ability to become a medicine for the treatment of chronic pain. This is underpinned by the following:
THUS, PN6047 can be the drug of choice to combat chronic pain and other conditions involving sensory hypersensitivity such as chronic cough and itch.
The advantages with PN6047, our selective, biased DOR agonist, versus traditional medicines in treating cronic pain are potentially substantial.
vs Conventional Opioids:
Better efficacy in sensory hypersensitivity disorders; no μ-receptor side effects; no analgesic tolerance; no abuse potential.
Lower dose; no dose adjustment in renal insufficiency patients; no abuse potential; no cytochrome enzyme inhibition so less drug interactions.
Lower dose; no cardiovascular complications; lower metabolite exposure; no dose adjustment in hepatic insufficiency patients; no significant food or drug interactions.